To report a case of neurological immune-related adverse events (irAEs) following anti-PD-1 immunotherapy in a cervical cancer patient, highlighting its significance in the context of limited existing literature.
Key Findings:
The patient experienced delayed neurological irAEs, specifically myositis and myelitis, after immunotherapy, emphasizing the need for vigilance.
Initial treatment with cemiplimab led to a partial response, but subsequent complications arose during steroid tapering, indicating the unpredictable nature of irAEs.
Structured follow-up is crucial for early detection and management of irAEs, particularly in patients receiving anti-PD-1 therapy.
Interpretation:
This case underscores the potential for severe and delayed neurological irAEs in patients receiving anti-PD-1 therapy, highlighting the need for vigilance in monitoring and managing these complications, and suggesting the implementation of structured follow-up protocols.
Limitations:
The report is based on a single case, limiting generalizability and introducing potential biases in case reporting.
Limited existing literature on neurological irAEs in cervical cancer patients receiving immunotherapy.
Conclusion:
As immunotherapy becomes more prevalent in treating advanced cervical cancer, awareness and management of neurological irAEs are essential for improving patient outcomes, with specific strategies recommended for clinicians.
